REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
Latest Information Update: 02 Feb 2024
Price :
$35 *
At a glance
- Drugs Estradiol (Primary) ; Polycarbophil (Primary)
- Indications Atrophic vaginitis
- Focus Therapeutic Use
- Acronyms REVIVE
- 26 Jan 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 26 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 18 Nov 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2024.